{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:29:04Z","timestamp":1791822544165,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010240","name":"National Planning Office of Philosophy and Social Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019033","name":"Key Research and Development Program of Liaoning Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015936","name":"Guangzhou University of Chinese Medicine International Institute for Translational Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015936","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lungcan.2026.108930","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:07:22Z","timestamp":1768262842000},"page":"108930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence"],"prefix":"10.1016","volume":"213","author":[{"given":"Xiaoyu","family":"Gang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suya","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-0147","authenticated-orcid":false,"given":"Heming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0183-144X","authenticated-orcid":false,"given":"Mingfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.108930_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.lungcan.2026.108930_b0010","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.108930_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174103","article-title":"Molecular biology and therapeutic perspectives for K-Ras mutant non-small cell lung cancers","volume":"14","author":"Cekani","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.lungcan.2026.108930_b0020","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41698-024-00644-4","article-title":"Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC","volume":"8","author":"Sisoudiya","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.108930_b0030","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2026.108930_b0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7477","key":"10.1016\/j.lungcan.2026.108930_b0045","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.lungcan.2026.108930_b0050","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.lungcan.2026.108930_b0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.lungcan.2026.108930_b0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.108930_b0065","doi-asserted-by":"crossref","unstructured":"I.A. Jaiyesimi, N.B. Leighl, N. Ismaila, K. Alluri, N. Florez, S. Gadgeel, et al., Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living guideline, Version 2023.3, J. Clin. Oncol. 2024, 42(11):e1-e22. doi:10.1200\/jco.23.02744.","DOI":"10.1200\/JCO.23.02744"},{"issue":"4","key":"10.1016\/j.lungcan.2026.108930_b0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"8","key":"10.1016\/j.lungcan.2026.108930_b0075","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.lungcan.2026.108930_b0080","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1158\/1078-0432.CCR-21-2719","article-title":"Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer","volume":"28","author":"Ricciuti","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.108930_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104554","article-title":"KRAS mutations in advanced non-small cell lung cancer: from biology to novel therapeutic strategies","volume":"205","author":"Liguori","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0090","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1186\/s12885-022-10236-9","article-title":"A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0095","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s12885-025-13868-9","article-title":"PD-1\/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study","volume":"25","author":"Wei","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2026.108930_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102317","article-title":"Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer","volume":"53","author":"Qiang","year":"2025","journal-title":"Transl. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2026.108930_b0105","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10030","key":"10.1016\/j.lungcan.2026.108930_b0110","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"10066","key":"10.1016\/j.lungcan.2026.108930_b0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lungcan.2026.108930_b0120","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC","volume":"34","author":"Mok","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.108930_b0125","doi-asserted-by":"crossref","first-page":"S1327","DOI":"10.1016\/j.annonc.2021.08.2129","article-title":"LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy na\u00efve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.108930_b0130","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz453.002","article-title":"KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.108930_b0135","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial","volume":"10","author":"West","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2026.108930_b0140","doi-asserted-by":"crossref","first-page":"S1375","DOI":"10.1016\/j.annonc.2021.10.020","article-title":"4O Nivolumab (NIVO) \u00a0+ ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status","volume":"32","author":"Ramalingam","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108930_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102065","article-title":"Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial","volume":"8","author":"Borghaei","year":"2023","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.lungcan.2026.108930_b0150","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jtho.2024.09.1381","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic NSCLC: five-year overall survival outcomes from the phase 3 POSEIDON trial","volume":"20","author":"Peters","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"10378","key":"10.1016\/j.lungcan.2026.108930_b0160","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.108930_b0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509","article-title":"KRYSTAL-12: phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation","volume":"42","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108930_b0170","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/cpt.1956","article-title":"Relationship between progression-free survival, objective response rate, and overall survival in clinical trials of PD-1\/PD-L1 immune checkpoint blockade: a meta-analysis","volume":"108","author":"Ye","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.lungcan.2026.108930_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102542","article-title":"Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1\/PD-L1 immune checkpoint inhibitors plus chemotherapy","volume":"116","author":"Villacampa","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003024","article-title":"Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies","volume":"10","author":"Michielin","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.108930_b0185","doi-asserted-by":"crossref","first-page":"737","DOI":"10.21037\/tlcr-20-958","article-title":"KRAS(G12C)\/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (\u226550%) lung adenocarcinoma","volume":"10","author":"Frost","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2026.108930_b0190","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2023.12.015","article-title":"Outcome of first-line treatment with pembrolizumab according to KRAS\/TP53 mutational status for nonsquamous programmed death-ligand 1-high (\u226550%) NSCLC in the German national network genomic medicine lung cancer","volume":"19","author":"Bischoff","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108930_b0195","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.jtho.2019.01.011","article-title":"Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Jeanson","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.108930_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107510","article-title":"Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11\/KEAP1 comutations across PD-L1 levels","volume":"190","author":"Sun","year":"2024","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2026.108930_b0205","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2026.108930_b0210","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1002\/cam4.4739","article-title":"The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-mutant non-small cell lung cancer","volume":"11","author":"Chen","year":"2022","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.108930_b0215","first-page":"501","article-title":"The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers","volume":"16","author":"Konishi","year":"2000","journal-title":"Int. J. Oncol."},{"issue":"20","key":"10.1016\/j.lungcan.2026.108930_b0220","first-page":"4575","article-title":"Mutant ras oncogenes upregulate VEGF\/VPF expression: implications for induction and inhibition of tumor angiogenesis","volume":"55","author":"Rak","year":"1995","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2026.108930_b0225","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.108930_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105123","article-title":"Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA","volume":"10","author":"Carbone","year":"2025","journal-title":"ESMO Open"},{"issue":"8038","key":"10.1016\/j.lungcan.2026.108930_b0240","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.lungcan.2026.108930_b0245","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.108930_b0250","first-page":"169","article-title":"Adagrasib in KRYSTAL-12has not broken the KRAS G12C enigma code of the unspoken 6-month PFS barrier in NSCLC","volume":"15","author":"Lee","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"issue":"2","key":"10.1016\/j.lungcan.2026.108930_b0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.lungcan.2026.108930_b0260","doi-asserted-by":"crossref","first-page":"S1273","DOI":"10.1016\/j.annonc.2023.10.025","article-title":"LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.108930_b0265","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.3013","article-title":"A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors","volume":"43","author":"Ai","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.108930_b0270","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT019","article-title":"Abstract CT019: preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors","volume":"85","author":"Arbour","year":"2025","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2026.108930_b0275","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1556-0864(25)00201-1","article-title":"6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)","volume":"20","author":"Punekar","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.108930_b0280","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41392-025-02382-w","article-title":"Coinhibition of the MEK\/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer","volume":"10","author":"Lu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.lungcan.2026.108930_b0285","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","article-title":"608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)","volume":"35","author":"Park","year":"2024","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.108930_b0290","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.ccell.2025.05.006","article-title":"Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy","volume":"43","author":"Benton","year":"2025","journal-title":"Cancer Cell"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:05:21Z","timestamp":1774029921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"alternative-id":["S0169500226000255"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108930","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.108930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108930"}}